Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foster versus formoterol in severe COPD
NL-OMON38218Phase 3Active, not recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Foster arm with Formoterol control arm (2 arms). Primary endpoints: Change in pre-dose morning FEV1 from baseline to 12 weeks and COPD exacerbation rate. Started Oct 2010; status: active, not recruiting.
02
Drugs
beclometasone dipropionate + formoterolformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON38218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38218.